EXHIBIT 99.1

Contact:

Investors:                                          Media:
Ann Tanabe                                          Brad Miles
Encysive Pharmaceuticals                            BMC Communications
(713) 796-8822                                      (212) 477-9007 ext. 17

Hershel Berry
The Trout Group
(415) 392-3385


FOR IMMEDIATE RELEASE

ENCYSIVE PHARMACEUTICALS ANNOUNCES ITS MAJORITY-OWNED AFFILIATE, REVOTAR
BIOPHARMACEUTICALS AG, INITIATES TWO PHASE IIA CLINICAL TRIALS IN PSORIASIS AND
ATOPIC DERMATITIS

Houston, TX- (October 9, 2003)- Encysive Pharmaceuticals (NASDAQ: ENCY) today
announced that its majority-owned German affiliate, Revotar Biopharmaceuticals
AG, initiated two double-blind, placebo and standard drug controlled Phase IIa
clinical trials in psoriasis and atopic dermatitis. In both trials, a new
topical formulation of bimosiamose, a small molecule selectin antagonist will be
used.

"We are pleased with the progress Revotar has made with the selectin program,"
said Bruce D. Given, M.D. president and CEO of Encysive Pharmaceuticals Inc.
"The initiation of these trials along with the positive asthma results reported
in August, will add value to Revotar's selectin antagonist development program
in inflammatory diseases," Given added.

Bimosiamose is a pan-selectin antagonist under development by Revotar. In
addition to psoriasis and atopic dermatitis, the company is evaluating
bimosiamose in asthma. For a complete copy of the Revotar announcement please
visit the Revotar web site at www.revotar-ag.de

ABOUT REVOTAR BIOPHARMACEUTICALS AG

Revotar Biopharmaceuticals AG is a privately held German company, majority
owned by Encysive Pharmaceuticals. The other investors are bmp AG and Medipoint
Venture Funds GmbH, both located in Berlin, Germany. Revotar is located in
Henningsdorf, State of Brandenburg, Germany, and is committed to the discovery
and development of small molecule drugs to treat inflammation. Revotar
Biopharmaceuticals AG owns proprietary rights to the development of small
molecule antagonist Microphage Migration Inhibitor (MIF), and the Junctional
Adhesion Molecule-1 (JAM-1) and its interaction with LFA-1. Its lead compound
bimosiamose (small molecule selectin antagonist) is also being developed in
Phase II clinical trials for topical treatment of psoriasis and atopic
dermatitis. Other indications such as COPD, inflammatory bowel disease,
reperfusion injury, sepsis, rheumatoid arthritis and transplantation may also
become promising targets for selection antagonists. To learn more about Revotar
Biopharmaceuticals AG please visit their web site www.revotar-ag.de





ABOUT ENCYSIVE PHARMACEUTICALS

Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, sitaxsentan, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.


This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of research
and clinical goals and milestones of product candidates, attainment of required
government approvals, sales levels of our products and availability of financing
and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The company undertakes no duty to update of revise these
forward-looking statements.


                                      # # #